Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
  • COVID-19 Long-Haulers
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Wednesday, April 7

Antibody-based strategies in HIV therapy

Leronlimab in International Journal of Infectious Diseases

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

Local drug trial provides hope for COVID ‘long-haulers’

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Leronlimab and Long-Haulers

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Case Study of Critically Ill Person with COVID-19 on ECMO Successfully Treated with Leronlimab Published in Journal of Translational Autoimmunity

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

In The News

Investors

Investors

  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
    • Overview
    • Press Releases
    • In The News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • Overview
  • Press Releases
  • In The News
  • IR Calendar
  • Email Alerts

Dr. Yo – Is Leronlimab a Game Changer? Coronavirus (COVID-19) Treatment | How does Leronlimab work?

May 1, 2020

Fox News: Experimental coronavirus treatment leronlimab resulted in 'remarkable recoveries,' developer says

May 1, 2020

Targeted Oncology: Close to 50 Patients Treated with Leronlimab for COVID-19, Many Recover

Apr 30, 2020

BioQuick News: CytoDyn Describes Stunning Results for COVID-19 Treatment with Leronlimab; Drug Ends “Cytokine Storms,” Restores Lung Function, & Reduces Plasma Viral Load; Ventilated Patients Achieve Rapid Improvement & Some Can Be Ex-Tubated 48 Hours After Treatment

Apr 30, 2020

Proactive Investors: CytoDyn continues to report strong results from COVID-19 patients using Leronlimab

Apr 30, 2020

Insider Financial: Gilead (NASDAQ: GILD) Shares Jump On Trial Results and Fauci Despite 9.3% Mortality Rate After 14 Days

Apr 29, 2020

Fox News: Experimental coronavirus treatment leronlimab has delivered 'impressive' early results, developer says

Apr 27, 2020

BBC News: Coronavirus: Athlete's cancer treatment hopes dashed due to lockdown

Apr 26, 2020

KOIN-6 (Portland, OR): Vancouver biotech company tests COVID-19 treatment

Apr 25, 2020

New York Post: Trial for potential coronavirus drug remdesivir running ahead of schedule

Apr 25, 2020
RSS
  • « Previous
  • 1...
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next »
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
© 2021 CytoDyn Inc. All Rights Reserved.
  • Twitter
  • Facebookj
Privacy Policy Disclaimer Sitemap